BAYREUTH, Germany, March 21, 2011 /PRNewswire/ -- BioCer Entwicklungs GmbH, a Bayreuth, Germany based medical device manufacturer, are pleased to announce their attendance at the China Medical Equipment Fair (CMEF) Shenzhen, China 15th-19th April 2011. HaemoCer(TM) an Absorbable Polysaccharide Hemostat (APH) and Ti0(2)Mesh(TM) Hernia repair system will be on exhibit at the BioCer booth.
HaemoCer(TM) APH technology is delivered in a powder format developed to meet the challenges of problematic bleeding in surgery. Utilizing Biocer's Polysacharide Ultra-hydrophilic Resorbable Engineering (PURE) process modifies plant-based polymers to create a highly absorptive, biocompatible agent which enhances and accelerates the natural clotting cascade. The PURE technology format of HaemoCer(TM) APH contains no thrombin, collagen, or other human or animal components, and is resorbed within days.
TiO(2)Mesh(TM) is an implant utilizing a biocompatible coating for surgical Hernia repair. Ti0(2)Mesh(TM) combines multiple requirements, specifically addressing the needs of the laparoscopic surgeon. TiO(2)Mesh(TM) offers a complete solution to the laparoscopic surgeon and coincides with the advance and rapid growth of minimally invasive surgery in China.
Heinz-Josef Schmies, Managing Director of BioCer Entwicklungs Gmbh commented, "The introduction at the CMEF of HaemoCer(TM) APH and its proprietary, integrated PURE technology offers Asian-Pacific medical professionals an opportunity to examine directly the latest advance in polysaccharide hemostats. TiO(2)Mesh(TM) which encompasses a cutting edge coating technology combined with all the requirements of the ideal Hernia repair mesh offers a complete solution to unmet needs. We anticipate surgeons and patients in China and Asia-Pacific will benefit from these advanced technological innovations in Hernia repair and Hemostasis."
BioCer Entwicklungs GmbH is a privately-held medical device company and welcomes CMEF visitors to their booth H26, hall 2. For further information, distribution inquiries, and licensing options, please visit http://www.biocer-gmbh.de/en/.
Source: Philip MacPherson
SOURCE BioCer Entwicklungs GmbH